Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
5
×
boston top stories
deals
5
×
national blog main
life sciences
national top stories
san francisco blog main
startups
biotech
new york blog main
san francisco
san francisco top stories
boston
cancer
genentech
healthcare
medical devices
new york top stories
roche
san diego blog main
san diego top stories
vc
.406 ventures
accelerator
acetylon pharmaceuticals
airbnb
alphabet
amazon web services (aws)
ambys medicines
artificial intelligence (a.i.)
athelas
atomwise
benchling
biotechnology
broad institute of harvard and mit
brook byers
cancer immunotherapy
cell therapy
center for medicare and medicaid services
charles chu
What
big
5
×
startup
today
acquire
admits
advance
ago
agreed
aiming
ambys
announced
available
based
bigger
billion
bio
biosciences
biotech
biotechs
boston
broad
cas
cheaper
classes
collaborative
combinator
companies
company
confidence
control
crispr
deadly
deal
debuted
develop
diagnostics
didn’t
digital
diseases
dug
Language
unset
Current search:
deals
×
" boston blog main "
×
big
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Iora Health Goes Big With $100M to Advance Collaborative Care Model